HK inno.N - Public Comps and Valuation Multiples

HK inno.N Overview

About HK inno.N

HK Inno N Corp manufactures pharmaceutical products.

Founded

HQ

Employees

n/a

Website

inno-n.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $730M

LTM EBITDA $101M

EV

$1.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

HK inno.N Financials

As of September 2025, HK inno.N reported last 12-month revenue of $730M and EBITDA of $101M.

In the same period, HK inno.N generated $334M in LTM gross profit and $50.1M in net income.

See HK inno.N valuation multiples based on analyst estimates

HK inno.N P&L

In the most recent fiscal year, HK inno.N reported revenue of $628M and EBITDA of $88.3M.

HK inno.N expects next 12-month revenue of XXX and NTM EBITDA of XXX

See HK inno.N valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$730M	XXX	$628M	XXX	XXX	XXX
Gross Profit	$334M	XXX	$304M	XXX	XXX	XXX
Gross Margin	46%	XXX	48%	XXX	XXX	XXX
EBITDA	$101M	XXX	$88.3M	XXX	XXX	XXX
EBITDA Margin	14%	XXX	14%	XXX	XXX	XXX
EBIT	$73.1M	XXX	$61.7M	XXX	XXX	XXX
EBIT Margin	10%	XXX	10%	XXX	XXX	XXX
Net Profit	$50.1M	XXX	$43.1M	XXX	XXX	XXX
Net Margin	7%	XXX	7%	XXX	XXX	XXX
Net Debt	XXX	XXX	$262M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for HK inno.N including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $730M. EBITDA for the last twelve months was $101M. In the most recent fiscal year, HK inno.N achieved $628M in revenue and $88.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$730M	Analyst estimates available to subscribers	$628M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$334M	Analyst estimates available to subscribers	$304M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	45.8% gross margin	Analyst estimates available to subscribers	48.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$101M	Analyst estimates available to subscribers	$88.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	13.9% EBITDA margin	Analyst estimates available to subscribers	14.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$73.1M	Analyst estimates available to subscribers	$61.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	10.0% EBIT margin	Analyst estimates available to subscribers	9.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$50.1M	Analyst estimates available to subscribers	$43.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	6.9% net profit margin	Analyst estimates available to subscribers	6.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$262M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for HK inno.N

This financial data table provides comprehensive performance metrics for HK inno.N, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

HK inno.N generated $730M in revenue over the last twelve months.
The company achieved $101M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $334M.
Net income over the last twelve months reached $50.1M.

Fiscal Year Performance

In the most recent fiscal year, HK inno.N reported $628M in total revenue.
Fiscal year EBITDA was $88.3M.
The company maintained a gross profit margin of 48.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 14.1%.
Net profit margin reached 6.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for HK inno.N. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

HK inno.N Stock Performance

HK inno.N has current market cap of KRW 1.33T (or $931M), and EV of KRW 1.70T (or $1.2B).

Market Cap Evolution

HK inno.N Stock Data

As of October 17, 2025, HK inno.N's stock price is KRW 46950 (or $33).

See HK inno.N trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.2B	$931M	XXX	XXX	XXX	XXX	$1.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

HK inno.N Valuation Multiples

HK inno.N's trades at 1.9x EV/Revenue multiple, and 13.5x EV/EBITDA.

See valuation multiples for HK inno.N and 15K+ public comps

HK inno.N Financial Valuation Multiples

As of October 17, 2025, HK inno.N has market cap of $931M and EV of $1.2B.

Equity research analysts estimate HK inno.N's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

HK inno.N has a P/E ratio of 18.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$931M	XXX	$931M	XXX	XXX	XXX
EV (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV/Revenue	1.6x	XXX	1.9x	XXX	XXX	XXX
EV/EBITDA	11.7x	XXX	13.5x	XXX	XXX	XXX
EV/EBIT	16.3x	XXX	19.3x	XXX	XXX	XXX
EV/Gross Profit	3.6x	XXX	n/a	XXX	XXX	XXX
P/E	18.6x	XXX	21.6x	XXX	XXX	XXX
EV/FCF	33.1x	XXX	-85.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get HK inno.N Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

HK inno.N Margins & Growth Rates

HK inno.N's last 12 month revenue growth is 8%

HK inno.N's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

HK inno.N's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

HK inno.N's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for HK inno.N and other 15K+ public comps

HK inno.N Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	8%	XXX	12%	XXX	XXX	XXX
EBITDA Margin	14%	XXX	14%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	20%	XXX	XXX	XXX
Rule of 40	20%	XXX	22%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	33%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	18%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	39%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial